scholarly journals Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach

2019 ◽  
Vol 7 (1) ◽  
pp. 14-14 ◽  
Author(s):  
Francesco Cortiula ◽  
Giovanna De Maglio ◽  
Maria Giulia Cangi ◽  
Lorenzo Gerratana ◽  
Camilla Lisanti ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Third Generation ◽  
Tailored Therapy ◽  
Epidermal Growth

scholarly journals Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma

RSC Advances ◽  
2018 ◽  
Vol 8 (70) ◽  
pp. 40387-40394 ◽  
Author(s):  
Mohamed W. Attwa ◽  
Adnan A. Kadi ◽  
Hany W. Darwish ◽  
Ali S. Abdelhameed
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase Inhibitor ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitor ◽  
Growth Factor Receptor ◽  
Third Generation ◽  
Epidermal Growth ◽  
Egfr Tki

Olmutinib (OTB, Olita™) is an orally available third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

Sign in / Sign up

Export Citation Format

Share Document